Tag: brca

1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage ovarian cancer,...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage...
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). 2. BRCA1 methylation was detected in women of all ages, including newborns, suggesting that BRCA1 methylation happens at an embryonic stage. Evidence Rating Level: 3 (Average)     Study Rundown: Females with BRCA1 mutations...
1. Multiple breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) were identified in BRCA1 and BRCA2 genes and were found to confer varying degrees of risk for breast and ovarian cancer. Evidence Rating Level: 2 (Good) Study Rundown: BRCA1 and BRCA2 (i.e., breast cancer susceptibility genes) are human...
1. Olaparib monotherapy was associated with prolonged tumor response rate in advanced BRCA1/2-associated breast, ovarian, pancreatic, and prostate cancers. 2. Olaparib was well tolerated with common adverse side effects including anemia, fatigue, nausea, and vomiting. Evidence Rating Level: 3 (Average) Study Rundown: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously demonstrated...
1. A non-randomized control trial of 996 women at high risk for developing ovarian and tubal cancer found that 2.6% of cases had undetectable neoplasms on pathology after risk-reducing salpingo-oophorectomy. 2. Positive BRCA 1/2 mutation status, older age, postmenopausal status, and abnormal CA-125 levels were associated with clinically undetectable malignancies. Evidence...
1. Both prophylactic and therapeutic nipple-sparing mastectomies were associated with low locoregional occurrence or recurrence.  2. Occurrence or recurrence of cancer was not found within the preserved nipple-areolar complex.  Evidence Rating Level: 2 (Good)             Study Rundown: While prevalence of nipple-sparing mastectomies (NSM) is increasing, concern exists that...
1. The combination of an annual MRI and mammography in women at high risk for breast cancer demonstrated a high breast cancer detection rate.  2. The positive predictive value was higher for cancer detection by both MRI and mammography compared to MRI alone.  Evidence Rating Level: 2 (Good)  Study Rundown: Though only a...
Image: PD 1. Prophylactic oophorectomy is associated with reduced the risk of ovarian, fallopian tube, and peritoneal cancer by 80% in BRCA1 and BRCA2 mutation carriers. 2. Prophylactic oophorectomy reduces all-cause mortality by 77%. Evidence rating level: 2 (Good) Study Rundown: Prophylactic bilateral salpingo-oophorectomy has already been demonstrated to reduce the risk of...
Feb 3rd – JAMA - In spite of limited evidence for their use in this population, a substantial portion of women with uninformative BRCA test results chose to undergo RRSO and ovarian cancer screenings. Image: PD 1. In spite of limited evidence for their use in this population, a substantial portion...